A Phase 3 extension trial reported sustained seizure reductions and notable seizure-free rates for adjunctive cenobamate across focal seizure subtypes in adults, according to a multinational update. The results reinforce cenobamate’s role as a broad-spectrum option within focal epilepsy subgroups. While this is not a headline-grabbing approval event, extension data matters for payers and clinicians because it informs expectations around long-term durability, safety monitoring, and regimen selection after initial responders. For epilepsy drug developers, the update emphasizes the importance of demonstrating consistent benefit across clinically relevant subtypes rather than focusing on a narrow phenotype. Sponsors often face difficulties maintaining efficacy narratives in regulatory and reimbursement environments if benefit is inconsistent across stratified populations. Clinicians will likely use the data to refine treatment sequences, particularly for patients who have already cycled through multiple anti-seizure medications and require durable control without excessive adverse events.